NEWS | Innovation for Life

SINGAPORE, April 27, 2021 – Prestige Biopharma Limited, specializing in the development of antibody therapeutics, announced a strategic partnership with Cytiva on April 27, 2021. The signing ceremony was held at its affiliated company, Prestige Biologics in Osong, South Korea. Those attending included President and CEO of Cytiva Emmanuel Ligner, Vice President Commercial, Asia-Pacific of Cytiva Francis Van Parys, General Manager of Cytiva Korea Joon Ho Choi, Group Chairman and CEO of Prestige Biopharma Group Lisa Soyeon Park and Group Vice Chairman and COO of Prestige Biopharma Group Michael Jinwoo Kim.

Through this partnership, Cytiva will supply bioprocessing equipment for cell culture and purification that will be used for vaccine and biologics production. Cytiva will also be providing technologies and solutions for bio-manufacturing to help Prestige Biopharma to rapidly produce multiple vaccines and biologics.

Prestige Biopharma will be procuring a variety of bioprocessing equipment including 50 units of 2,000 litre single-use bioreactors and will be using them to produce Russia’s Sputnik V COVID-19 vaccine. Prestige Biopharma vaccine center’s test operation is expected to commence in August and aims to start full production of 100 million doses of vaccine DS (Drug Substance) per month from September this year.

Cytiva Korea’s General Manager, Mr. Joon Ho Choi commented, “we are very excited to enter into this partnership that will build a global-scale supply chain” and “hopefully our partnership will enable Prestige Biopharma with further production capabilities to assist in defeating the pandemic”. “Cytiva will also support PBP’s antibody therapeutics business as well” added Mr. Choi.

Dr. Lisa S. Park, CEO of Prestige Biopharma, commented: “Despite the current vaccine distribution, most of the global population unfortunately still lacks access to life-saving, essential COVID-19 vaccines and global vaccine developers are facing increasing challenges in rapidly building supply chains to meet the high demand,” and “with this novel partnership and our global-scale vaccine centre, PBP Group will contribute to the growing global demands of vaccine development and production in response to the current situation, and also for potential, viral pandemics of the future.”